Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Tara Neil

Family Medicine Wichita, KS Medical Doctor

NPI 1144299546 CMS profile 794377

2402 E 13Th St N, Wichita, KS 67214

Open in the dashboard

General payments

$15,772

14 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Tara Neil of Wichita, KS is reported in the CMS Open Payments database as having received $15,772 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $5,500 4
2021 General $5,500 4
2020 General $1,375 1
2019 General $3,397 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tara Neil
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Tara Neil were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Tara Neil Family Medicine median Middle half National median
2019 $3,397 $150 $41–$543 $163
2020 $1,375 $120 $32–$415 $114
2021 $5,500 $137 $35–$551 $132
2022 $0 $137 $37–$512 $149
2023 $5,500 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Organon LLC $8,250 6 payments
  2. Merck Sharp & Dohme Corporation $7,522 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,875 8 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $5,500 4 payments
  3. Travel and Lodging $354 1 payment
  4. Food and Beverage $43 1 payment
Products named General payments · program years 2019–2023
  1. NEXPLANON Womens Health $7,522 8 payments
  2. NEXPLANON Etonogestrel $5,500 4 payments
  3. Nexplanon Womens Health $2,750 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 94 drugs

Part D claims

4,465

Median for Family Practice: 1,826

Drug cost

$382,212

Median for Family Practice: $120,094

Branded share of claims

22.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 72 $69,228
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 63 $49,918
Eliquis Apixaban Brand 40 $41,020
Januvia Sitagliptin Phosphate Brand 40 $35,454
Jardiance Empagliflozin Brand 33 $32,946
Mounjaro Tirzepatide Brand 24 $25,724
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 25 $15,745
Trulicity Dulaglutide Brand 11 $12,500
Linzess Linaclotide Brand 14 $10,948
Farxiga Dapagliflozin Propanediol Brand 11 $9,737

The 10 drugs with the highest cost, of 94 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$1,528

Medicare's payments for the services billed

Medicare patients

27

Average age 64

Services billed

29

12 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 56%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record